Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke

Launched by MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES · Oct 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective different doses of a medication called ticagrelor, combined with aspirin, are at preventing further strokes in patients who have recently had an ischemic stroke or a high-risk transient ischemic attack (TIA). The trial will involve 100 patients at Bou-Ali Sina Hospital in Sari, Iran, and will compare two different treatment plans: one group will take a higher dose of ticagrelor for one month, while another group will take a lower dose for three months. The goal is to see which plan better reduces the chances of experiencing another stroke or serious TIA within the first year.

To be eligible for the trial, participants must have had a mild ischemic stroke within the past 24 hours or be at high risk for TIA, as determined by specific tests. Other important criteria include being free of certain heart conditions and having no significant blockages in the blood vessels supplying the brain. Participants will need to sign an informed consent form and will be monitored closely throughout the study. This trial is not yet recruiting, so it’s still in the planning stages, but it aims to provide valuable information that could help improve treatment for patients at risk of strokes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • signing inform consent,
• • recent ischemic stroke within 24 h,
• • diagnosed by brain CT or MRI mild stroke with NIHSS =\<8 and no evidence of large infarct in brain imaging
• • high risk TIA with ABCD \>4,
• • no cardioembolic source such as low E/F, MS, AF ,...
• • no specific etiology such as dissection, vasculitis, ...
• • no carotid stenosis \> 50 % in side of involvement
• Exclusion Criteria:
• • history of hypersensitivity to consumptive drug
• • any indication for anticoagulant therapy
• • acute phase treatment with intravenous thrombolysis or thrombectomy
• • any contraindication for consumptive drug
• • history of intracranial hemorrhage
• • history of GI bleeding during past 6 m
• • candidate for endarterectomy
• • history of coagulopathy
• • active hemorrhagic diathesis during randomization